Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Jan 16;94(1):69-73.
doi: 10.1038/sj.bjc.6602913.

'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'

J Bennouna  1 , H Perrier, B Paillot, F Priou, J H Jacob, M Hebbar, S Bordenave, J F Seitz, F Cvitkovic, E Dorval, K Malek, D Tonelli, J Y Douillard
Affiliations
Clinical Trial

'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'

J Bennouna et al. Br J Cancer. .

Abstract

This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease. Between February 2002 and October 2002, 64 patients received UFT 300 mg m(-2) day(-1) and LV 90 mg day(-1) from day 1 to day 14 combined with oxaliplatin 130 mg m(-2) on day 1, every 3 weeks. All patients were evaluable for safety analysis and 58 of 64 patients were eligible for efficacy. Responses were reviewed by an independent review committee. Of the 58 per-protocol defined assessable patients, 1 complete response and 20 partial responses were observed yielding a response rate of 34% (95% CI: 22-47). The median response duration was 8.74 months (range 1.6-14). The median time to progression and the median survival were 5.88 months (95% CI: 4.34-8.21) and 18.2 months (95% CI: 10-20.7), respectively. Diarrhoea and peripheral neuropathy were the most frequent and predictable toxicities. These events were reversible, noncumulative and manageable. Grade 3 diarrhoea occurred in only 11% of the patients. No grade 4 gastrointestinal toxicity was reported in the study. The incidence of grade 3/4 (National Cancer Institute Common Toxicity Criteria 2: NCI-CTC 2) peripheral neuropathy was 15%. Haematological toxicity was of mild to moderate intensity with 10% of the patients with Grade 3/4 neutropenia without any episode of complication. The TEGAFOX regimen, a new combination using UFT/LV and oxaliplatin every 3 weeks is feasible on an outpatient basis. The combination is safe and active and may offer a promising alternative to the intravenous route. Nevertheless this efficacy results should be confirmed by randomized phase III trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median Survival – Kaplan–Meier curve.
See this image and copyright information in PMC

References

    1. Ansfield FJ, Kallas GJ, Singson JP (1983) Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1: 107–110 - PubMed
    1. Anttila MI, Sotaniemi EA, Kairaluoma MI, Mokka RE, Sundquist HT (1983) Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10: 150–153 - PubMed
    1. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD, for the Swiss Group for Clinical Cancer Research (2002b) Phase II study of capecitabine and oxaliplatin in first- and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20: 1759–1766 - PubMed
    1. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002a) Patient preference and pharmacokinetics of oral modulated UFT vs intravenous fluorouracil and leucovorin trial in advanced colorectal cancer. Eur J Cancer 38: 349–358 - PubMed
    1. Carmichael J, Popiela T, radstone D, Falk S, Borner M, Oza M, Skovsgaard T, Munier S, Martin S (2002) Randomized compartive study of Tegafur/Uracil and Oral Leucovorin vs parenteral Flourouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 17: 3617–3627 - PubMed

Publication types

MeSH terms

Supplementary concepts